tradingkey.logo

Eli Lilly and Co

LLY
1071.390USD
-5.090-0.47%
Close 12/23, 16:00ETQuotes delayed by 15 min
1.01TMarket Cap
52.28P/E TTM

Eli Lilly and Co

1071.390
-5.090-0.47%

More Details of Eli Lilly and Co Company

Eli Lilly and Company, commonly referred to as Lilly, is an American multinational pharmaceutical corporation based in Indianapolis, Indiana, with offices in 18 countries and products available in approximately 125 nations. Founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran from the American Civil War, the company carries his name.

As of October 2024, Lilly has achieved the status of the most valuable drug company in the world, boasting a market capitalization of $842 billion, marking the highest valuation ever recorded for a pharmaceutical company. The firm ranks 127th on the Fortune 500, reporting revenues of $34.12 billion. Additionally, it is positioned 221st on the Forbes Global 2000 list, which encompasses the largest publicly traded companies globally, and 252nd on Forbes' list of "America's Best Employers."

Lilly is recognized for its antidepressant medications, including Prozac and Cymbalta, as well as the antipsychotic drug Zyprexa. Its primary revenue sources are the diabetes treatments Humalog and Trulicity.

The company was a pioneer in mass-producing both the polio vaccine, created in 1955 by Jonas Salk, and insulin. Lilly was among the first in the pharmaceutical sector to manufacture human insulin using recombinant DNA technology, producing products like Humulin, Humalog, and the first approved biosimilar insulin in the U.S., known as Basaglar. Additionally, Lilly introduced exenatide to the market as the first of the GLP-1 receptor agonists, followed by highly successful medications in this category, such as Mounjaro and Zepbound.

By 1997, Lilly had become both the largest corporation and the largest philanthropic benefactor in Indiana. In 2009, it pleaded guilty to illegally marketing Zyprexa and agreed to a substantial $1.415 billion settlement, which included a criminal fine of $515 million, making it the largest ever in a healthcare-related case and the highest criminal fine levied against a single corporation in a U.S. criminal prosecution at that time.

Lilly is a full member of the Pharmaceutical Research and Manufacturers of America, as well as the European Federation of Pharmaceutical Industries and Associations.

Eli Lilly and Co Info

Ticker SymbolLLY
Company nameEli Lilly and Co
IPO dateJul 09, 1970
CEORicks (David A)
Number of employees47000
Security typeOrdinary Share
Fiscal year-endJul 09
AddressLilly Corporate Ctr
CityINDIANAPOLIS
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code46285
Phone13172762000
Websitehttps://www.lilly.com/
Ticker SymbolLLY
IPO dateJul 09, 1970
CEORicks (David A)

Company Executives of Eli Lilly and Co

Name
Name/Position
Position
Shareholding
Change
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%
Dr. Katherine Baicker, Ph.D.
Dr. Katherine Baicker, Ph.D.
Independent Director
Independent Director
23.37K
+0.93%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
19.72K
+77.63%
Mr. Lucas E. Montarce
Mr. Lucas E. Montarce
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
14.69K
+5.12%
Mr. Eric Dozier
Mr. Eric Dozier
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
9.84K
+15.72%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. J. Erik Fyrwald
Mr. J. Erik Fyrwald
Independent Director
Independent Director
74.57K
+0.30%
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+13.18%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
Executive Vice President, President of Lilly Cardiometabolic Health and President, Lilly USA
54.13K
+20.12%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
39.73K
-0.04%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President, President of Lilly International
Executive Vice President, President of Lilly International
26.26K
-4.54%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
25.66K
-41.06%

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
Other
3.42B
21.95%
By RegionUSD
Name
Revenue
Proportion
U.S.
10.81B
69.51%
Europe
2.57B
16.55%
Other foreign countries
1.18B
7.60%
Japan
521.00M
3.35%
China
465.90M
2.99%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Diabetes-Mounjaro
5.20B
33.42%
Diabetes-Zepbound
3.38B
21.73%
Oncology-Verzenio
1.49B
9.57%
Diabetes-Trulicity
1.09B
7.02%
Diabetes-Other Diabetes
980.40M
6.30%
Other
3.42B
21.95%

Shareholding Stats

Updated: Wed, Nov 12
Updated: Wed, Nov 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
Other
68.21%
Shareholders
Shareholders
Proportion
Lilly Endowment, Inc.
9.75%
The Vanguard Group, Inc.
8.52%
PNC Investments LLC
5.41%
BlackRock Institutional Trust Company, N.A.
4.43%
State Street Investment Management (US)
3.67%
Other
68.21%
Shareholder Types
Shareholders
Proportion
Investment Advisor
45.37%
Investment Advisor/Hedge Fund
18.69%
Foundation
9.75%
Research Firm
2.04%
Pension Fund
1.89%
Bank and Trust
1.84%
Insurance Company
1.48%
Sovereign Wealth Fund
1.29%
Hedge Fund
0.74%
Other
16.91%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
5762
789.85M
83.53%
-6.48M
2025Q2
5717
798.76M
84.28%
+2.87M
2025Q1
5710
800.38M
84.44%
+5.04M
2024Q4
5528
795.43M
83.87%
+627.51K
2024Q3
5177
793.57M
83.49%
-5.03M
2024Q2
5068
795.80M
83.72%
-2.01M
2024Q1
4916
795.04M
83.62%
-6.22M
2023Q4
4670
799.46M
84.21%
-2.37M
2023Q3
4354
800.21M
84.30%
-1.19M
2023Q2
4197
799.48M
84.22%
-4.32M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Lilly Endowment, Inc.
95.49M
10.09%
-243.99K
-0.25%
Sep 30, 2025
The Vanguard Group, Inc.
80.05M
8.46%
+1.17M
+1.49%
Jun 30, 2025
PNC Investments LLC
51.08M
5.4%
-9.49K
-0.02%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
41.30M
4.36%
-168.44K
-0.41%
Jun 30, 2025
State Street Investment Management (US)
34.51M
3.65%
+69.02K
+0.20%
Jun 30, 2025
Capital Research Global Investors
20.76M
2.19%
+5.01M
+31.81%
Jun 30, 2025
Fidelity Management & Research Company LLC
24.36M
2.57%
-2.82M
-10.39%
Jun 30, 2025
Geode Capital Management, L.L.C.
18.13M
1.92%
-397.62K
-2.15%
Jun 30, 2025
Capital World Investors
17.63M
1.86%
-748.08K
-4.07%
Jun 30, 2025
Wellington Management Company, LLP
13.99M
1.48%
+1.28M
+10.09%
Jun 30, 2025
View more

Related ETFs

Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
VanEck Pharmaceutical ETF
47.56%
iShares U.S. Pharmaceuticals ETF
25.23%
Harbor Health Care ETF
18.24%
Roundhill GLP-1 & Weight Loss ETF
16.7%
Health Care Select Sector SPDR Fund
14.06%
Proshares Ultra Health Care
13.57%
iShares U.S. Healthcare ETF
13.54%
Amplify Weight Loss Drug & Treatment ETF
11.93%
Fidelity MSCI Health Care Index ETF
11.73%
Goldman Sachs Future Health Care Equity ETF
10.84%
View more
VanEck Pharmaceutical ETF
Proportion47.56%
iShares U.S. Pharmaceuticals ETF
Proportion25.23%
Harbor Health Care ETF
Proportion18.24%
Roundhill GLP-1 & Weight Loss ETF
Proportion16.7%
Health Care Select Sector SPDR Fund
Proportion14.06%
Proshares Ultra Health Care
Proportion13.57%
iShares U.S. Healthcare ETF
Proportion13.54%
Amplify Weight Loss Drug & Treatment ETF
Proportion11.93%
Fidelity MSCI Health Care Index ETF
Proportion11.73%
Goldman Sachs Future Health Care Equity ETF
Proportion10.84%

Dividend

A total of 18.06B USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Oct 27, 2025
LLY.NB Final Cash Dividend of gross USD 1.5 paid on Dec 10, 2025 going ex on Nov 14, 2025
Nov 14, 2025
Dec 10, 2025
Nov 14, 2025
Jun 23, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Sep 10, 2025 going ex on Aug 15, 2025
Aug 15, 2025
Sep 10, 2025
Aug 15, 2025
May 05, 2025
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Jun 10, 2025 going ex on May 16, 2025
May 16, 2025
Jun 10, 2025
May 16, 2025
Dec 09, 2024
LLY.NB Interim Cash Dividend of gross USD 1.5 paid on Mar 10, 2025 going ex on Feb 14, 2025
Feb 14, 2025
Mar 10, 2025
Feb 14, 2025
Oct 28, 2024
LLY.NB Final Cash Dividend of gross USD 1.3 paid on Dec 10, 2024 going ex on Nov 15, 2024
Nov 15, 2024
Dec 10, 2024
Nov 15, 2024
Jun 24, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Sep 10, 2024 going ex on Aug 15, 2024
Aug 15, 2024
Sep 10, 2024
Aug 15, 2024
May 06, 2024
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Jun 10, 2024 going ex on May 15, 2024
May 16, 2024
Jun 10, 2024
May 15, 2024
Dec 08, 2023
LLY.NB Interim Cash Dividend of gross USD 1.3 paid on Mar 08, 2024 going ex on Feb 14, 2024
Feb 15, 2024
Mar 08, 2024
Feb 14, 2024
Nov 01, 2023
LLY.NB Final Cash Dividend of gross USD 1.13 paid on Dec 08, 2023 going ex on Nov 14, 2023
Nov 15, 2023
Dec 08, 2023
Nov 14, 2023
Jun 26, 2023
LLY.NB Interim Cash Dividend of gross USD 1.13 paid on Sep 08, 2023 going ex on Aug 14, 2023
Aug 15, 2023
Sep 08, 2023
Aug 14, 2023
View more

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data

FAQs

Who are the top five shareholders of Eli Lilly and Co?

The top five shareholders of Eli Lilly and Co are:
Lilly Endowment, Inc. holds 95.49M shares, accounting for 10.09% of the total shares.
The Vanguard Group, Inc. holds 80.05M shares, accounting for 8.46% of the total shares.
PNC Investments LLC holds 51.08M shares, accounting for 5.40% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 41.30M shares, accounting for 4.36% of the total shares.
State Street Investment Management (US) holds 34.51M shares, accounting for 3.65% of the total shares.

What are the top three shareholder types of Eli Lilly and Co?

The top three shareholder types of Eli Lilly and Co are:
Lilly Endowment, Inc.
The Vanguard Group, Inc.
PNC Investments LLC

How many institutions hold shares of Eli Lilly and Co (LLY)?

As of 2025Q3, 5762 institutions hold shares of Eli Lilly and Co, with a combined market value of approximately 789.85M, accounting for 83.53% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -0.75%.

What is the biggest source of revenue for Eli Lilly and Co?

In FY2025Q2, the Diabetes-Mounjaro business generated the highest revenue for Eli Lilly and Co, amounting to 5.20B and accounting for 33.42% of total revenue.
KeyAI